Company: TYRA
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0000950170-25-046124
Chunk: 249

Company: Tyra Biosciences, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 8
Chunk 249
---
 did not impact the financial statements. See Note 13, Segment Information, for disclosures related to the adoption of ASU 2023-07. Issued Accounting Pronouncements Not Yet AdoptedIn November 2024, the FASB issued ASU 2024-03, "Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses". ASU 2024-03 requires public entities to disclose specified information about certain costs and expenses on an interim and annual basis and is effective for annual reporting periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027, with early adoption permitted. The new standard is expected to be applied prospectively, but retrospective application is permitted. The Company is currently evaluating the impact of ASU 2024-03 on the financial statements and related disclosures.In December 2023, the FASB issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures.” ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for public entities with annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of ASU 2023-09 on its financial statements and related disclosures.

2. Fair Value MeasurementsThe following tables show the Company’s cash, cash equivalents, marketable securities, and restricted cash measured at fair value as of December 31, 2024 and 2023 (in thousands):

        December 31, 2024

        Total
         
        Quoted prices in active markets for identical assets (Level 1)
         
        Significant other observable inputs (Level 2)
         
        Significant unobservable inputs (Level 3)

        Cash and cash equivalents:

           Cash and money market funds
        $
        91,966
         
        $
        91,966
         
        $
        —
         
        $
        —

        Restricted cash:

           Cash
         
        1,000

        1,000

        —

        —

        Marketable securities:

           U.S. Treasury securities
         
        122,980

        —

        122,980

        —

           U.S. government